Treatment of neuromyelitis optica/neuromyelitis optica spectrum disorders with methotrexate

BMC Neurology

Volumn 14, Issue 1, 2014, Pages

  Ramanathan, Ramnath S ^a   Malhotra, Konark ^a   Scott, Thomas ^a  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

Immunosuppressant therapy; Methotrexate; Neuromyelitis optica; Neuromyelitis optica spectrum disorders

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; IMMUNOGLOBULIN G; METHOTREXATE; METHYLPREDNISOLONE; PREDNISONE; RITUXIMAB; CORTICOSTEROID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DRUG DOSE TITRATION; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EXPANDED DISABILITY STATUS SCALE; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LONG TERM CARE; LOW DRUG DOSE; MALE; MIDDLE AGED; MYELOOPTIC NEUROPATHY; PLASMAPHERESIS; RECURRENCE RISK; RETROSPECTIVE STUDY; DRUG MEGADOSE; DRUG PULSE THERAPY; FOLLOW UP; MEDICAL RECORD REVIEW; RELAPSE; STEROID THERAPY; TREATMENT FAILURE;

ADULT; AGED; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; METHOTREXATE; MIDDLE AGED; NEUROMYELITIS OPTICA; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84898839925     PISSN: None     EISSN: 14712377     Source Type: Journal    
DOI: 10.1186/1471-2377-14-51     Document Type: Article

References (18)

1. Pellkofer HL, Krumbholz M, Berthele A, Hemmer B, Gerdes LA, Havla LA, Bittner R, Canis M, Meinl E, Hohlfeld R, Kuempfel T. Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab. Neurology 2011, 76:1310-1315. 10.1212/WNL.0b013e3182152881, 21482945.
2. Allbutt T. On the ophthalmoscopic signs of spinal disease. Lancet 1870, 1:76-78.
3. Wingerchuk DM, Hogancamp WF, O'Brien PC, Weinshenker BG. The clinical course of neuromyelitis optica (Devic's syndrome). Neurology 1999, 53:1107-1114. 10.1212/WNL.53.5.1107, 10496275.
4. Bennett JL, Lam C, Kalluri SR, Salkali P, Bautista K, Dupree C, Glogowska M, Case D, Antel JP, Owens GP, Gilden D, Nessier S, Stadelmann C, Hemmer B. Intrathecal pathogenic anti-aquaporin-4 antibodies in early neuromyelitis optica. Ann Neurol 2009, 66:617-629. 10.1002/ana.21802, 3180961, 19938104.
5. Bradl M, Misu T, Takahashi T, Watanabe M, Mader S, Reindl M, Adzemovic M, Bauer J, Berger T, Fujihara K, Itoyama Y, Lassmann H. Neuromyelitis optica: pathogenicity of patient immunoglobulin in vivo. Ann Neurol 2009, 66:630-643. 10.1002/ana.21837, 19937948.
6. Hinson SR, Pittock SJ, Lucchinetti CF, Roemer SF, Fryer JP, Kryzer TJ, Lennon VA. Pathogenic potential of IgG binding to water channel extracellular domain in neuromyelitis optica. Neurology 2007, 69:2221-2231. 10.1212/01.WNL.0000289761.64862.ce, 17928579.
7. Uzawa A, Mori M, Sato Y, Masuda S, Kuwabara S. CSF interleukin-6 level predicts recovery from neuromyelitis optica relapse. J Neurol Neurosurg Psychiatry 2012, 83:339-340. 10.1136/jnnp.2011.241760, 21429904.
8. Chihara N, Aranami T, Sato W, Miyazaki Y, Miyake S, Okamoto T, Ogawa M, Toda T, Yamamura T. Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica. Proc Natl Acad Sci U S A 2011, 108:3701-3706. 10.1073/pnas.1017385108, 3048150, 21321193.
9. Sellner J, Boggild M, Clanet M, Hintzen RQ, Illes Z, Montalban X, Du Pasquier RA, Polman CH, Sorensen PS, Hemmer B. EFNS guidelines on diagnosis and management of neuromyelitis optica. Eur J Neurol 2010, 17:1019-1032. 10.1111/j.1468-1331.2010.03066.x, 20528913.
10. Jacob A, Matiello M, Weinshenker BG, Wingerchuk DM, Lucchinetti C, Shuster E, Carter J, Keegan BM, Kantarci OH, Pittock SJ. Treatment of neuromyelitis optica with mycophenolate mofetil retrospective analysis of 24 patients. Arch Neurol 2009, 66:1128-1133.
11. Costanzi C, Matiello M, Lucchinetti CF, Weinshenker BG, Pittock SJ, Mandrekar J, Thapa P, Mckeon A. Azathioprine tolerability, efficacy, and predictors of benefit in neuromyelitis optica. Neurology 2011, 77:659-666. 10.1212/WNL.0b013e31822a2780, 21813788.
12. Jacob A, Weinshenker BG, Violich I, McLinskey N, Krupp L, Fox RJ, Wingerchuk DM, Boggild M, Constantinescu CS, Miller A, De Angelis T, Matiello M, Cree BA. Treatment of neuromyelitis optica with rituximab retrospective analysis of 25 patients. Arch Neurol 2008, 65:1443-1448.
13. Pittock SJ, Lennon VA, Mckeon A, Mandrekar J, Weinshenker BG, Lucchinetti CF, O'Toole O, Wingerchuk DM. Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study. Lancet Neurol 2013, 12:554-562. 10.1016/S1474-4422(13)70076-0, 23623397.
14. Kieseier BC, Stuve O, Dehmel T, Goebels N, Leussink VI, Mausberg AK, Ringelstein M, Turowski B, Aktas O, Antoch G, Hartung HP. Disease amelioration with tocilizumab in a treatment-resistant patient with neuromyelitis optica. JAMA Neurol 2013, 70:390-393. 10.1001/jamaneurol.2013.668, 23599943.
15. Minagar A, Sheremata WA. Treatment of Devic's disease with methotrexate and prednisone. Int J MS Care 2000, 2:43-49.
16. Kitley J, Elsone L, George J, Waters P, Woodhall M, Vincent A, Jacob A, Leite MI, Palace J. Methotrexate is an alternative to azathioprine in neuromyelitis optica spectrum disorders with aquaporin-4 antibodies. J Neurol Neurosurg Psychiatry 2013, 84:918-921. 10.1136/jnnp-2012-304774, 23467418.
17. Johnston A, Gudjonsson JE, Sigmundsdottir H, Ludviksson BR, Valdimarsson H. The anti-inflammatory action of methotrexate is not mediated by lymphocyte apoptosis, but by the suppression of activation and adhesion molecules. Clin Immunol 2005, 114(2):154-163. 10.1016/j.clim.2004.09.001, 15639649.
18. Wasko MCM, Dasgupta A, Hubert H, Fries JF, Ward MM. Propensity-adjusted association of methotrexate with overall survival in rheumatoid arthritis. Arthritis Rheum 2013, 65:334-342. 10.1002/art.37723, 3558553, 23044791.